Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections.

Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase III SUNRISE-3 clinical trial for the treatment of patients with COVID-19.

The company also develops AT-752, a drug that is in Phase II clinical trial for the treatment and prophylaxis of dengue; and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, and Zika virus, as well as Ruzasvir, an investigational NS5A inhibitor for the treatment of chronic HCV infection.

It also develops a co-formulated, oral, pan-genotypic fixed dose combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virous (HCV); It has a license agreement with Merck & Co, Inc. development, manufacture, and commercialization of ruzasvir for the treatment of HCV.

Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.